Treatment with Axatilimab in Chronic GVHD: How it Works and Insights into Treatment Efficacy

The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.

Pacritinib showed early activity and was safe for patients with multi-refractory chronic graft-vs-host disease.

MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.

An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and what clinicians can do to mitigate these disparities.

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.